Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
Study Results
Related Studies
Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment (HALT-C)
This study is ongoing, but not recruiting participants.
Study NCT00006164 Information provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First Received: August 8, 2000 Last Updated: September 3, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Chronic Hepatitis C
Cirrhosis, Liver
Fibrosis, Liver
Hepatic Cirrhosis
Additional conditions recognized in this trial
Fibrosis
Hepatitis
Hepatitis C
Hepatitis C, Chronic
Hepatitis, Chronic
Liver Cirrhosis
More general conditions related to this trial
Digestive System Diseases
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Pathologic Processes
RNA Virus Infections
Virus Diseases
Interventions listed in this trial
Peginterferon alfa-2a + Ribavirin
Peginterferon alfa-2a
Additional drug interventions recognized in this trial
Antiviral Agents
Interferon Alfa-2a
Ribavirin
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antimetabolites
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of Allergy and Infectious Diseases (NIAID)
National Center on Minority Health and Health Disparities (NCMHD)
National Cancer Institute (NCI)
Hoffmann-La Roche
Back to top of Main Content
